Jose Osorio MD, FHRS , Daniela Hincapie MD , Allyson L. Varley PhD , Joshua R. Silverstein MD, FHRS , Carlos D. Matos MD , Amit J. Thosani MD, FHRS , Christopher Thorne PhD , Benjamin D’Souza MD, FHRS , Isabella Alviz MD , Mohamed Gabr MD , Anil Rajendra MD, FHRS , Saumil Oza MD , Dinesh Sharma MD, MPH, FHRS , Carolina Hoyos MD , Matthew J. Singleton MD, FHRS , Chinmaya Mareddy MD , Alejandro Velasco MD , Paul C. Zei MD, PhD, FHRS , William H. Sauer MD, FHRS , Jorge E. Romero MD, FHRS
{"title":"高频低潮气量通气可改善持续性心房颤动消融的手术和长期临床结果:前瞻性多中心登记。","authors":"Jose Osorio MD, FHRS , Daniela Hincapie MD , Allyson L. Varley PhD , Joshua R. Silverstein MD, FHRS , Carlos D. Matos MD , Amit J. Thosani MD, FHRS , Christopher Thorne PhD , Benjamin D’Souza MD, FHRS , Isabella Alviz MD , Mohamed Gabr MD , Anil Rajendra MD, FHRS , Saumil Oza MD , Dinesh Sharma MD, MPH, FHRS , Carolina Hoyos MD , Matthew J. Singleton MD, FHRS , Chinmaya Mareddy MD , Alejandro Velasco MD , Paul C. Zei MD, PhD, FHRS , William H. Sauer MD, FHRS , Jorge E. Romero MD, FHRS","doi":"10.1016/j.hrthm.2024.07.094","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>High-frequency, low-tidal volume (HFLTV) ventilation increases the efficacy and efficiency of radiofrequency catheter ablation (RFCA) of paroxysmal atrial fibrillation. Whether those benefits can be extrapolated to RFCA of persistent atrial fibrillation (PeAF) is undetermined.</div></div><div><h3>Objective</h3><div>The purpose of this study was to evaluate whether using HFLTV ventilation during RFCA in patients with PeAF is associated with improved procedural and long-term clinical outcomes compared to standard ventilation (SV).</div></div><div><h3>Methods</h3><div>In this prospective multicenter registry (REAL-AF), patients who had undergone pulmonary vein isolation (PVI) + posterior wall isolation (PWI) for PeAF using either HFLTV ventilation or SV were included. The primary efficacy outcome was freedom from all-atrial arrhythmias at 12 months. Secondary outcomes included procedural and long-term clinical outcomes and complications.</div></div><div><h3>Results</h3><div>A total of 210 patients were included (HFLTV=95 vs. SV=115) in the analysis. There were no differences in baseline characteristics between the groups. Procedural time (80 [66–103.5] minutes vs 110 [85–141] minutes; <em>P</em> <.001), total radiofrequency (RF) time (18.73 [13.93–26.53] minutes vs 26.15 [20.30–35.25] minutes; <em>P</em> <.001), and pulmonary vein RF time (11.35 [8.78–16.69] minutes vs 18 [13.74–24.14] minutes; <em>P</em> <.001) were significantly shorter using HFLTV ventilation compared with SV. Freedom from all-atrial arrhythmias was significantly higher with HFLTV ventilation compared with SV (82.1% vs 68.7%; hazard ratio 0.41; 95% confidence interval [0.21–0.82]; <em>P</em> = .012), indicating a 43% relative risk reduction and a 13.4% absolute risk reduction in all-atrial arrhythmia recurrence. There was no difference in long-term procedure-related complications between the groups (HFLTV 1.1% vs SV 0%, <em>P</em> = .270).</div></div><div><h3>Conclusion</h3><div>In patients undergoing RFCA with PVI + PWI for PeAF, the use of HFLTV ventilation was associated with higher freedom from all-atrial arrhythmias at 12-month follow-up, with significantly shorter procedural and RF times compared to SV, while reporting a similar safety profile.</div></div>","PeriodicalId":12886,"journal":{"name":"Heart rhythm","volume":"22 2","pages":"Pages 432-442"},"PeriodicalIF":5.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"High-frequency low-tidal volume ventilation improves procedural and long-term clinical outcomes in persistent atrial fibrillation ablation: Prospective multicenter registry\",\"authors\":\"Jose Osorio MD, FHRS , Daniela Hincapie MD , Allyson L. Varley PhD , Joshua R. Silverstein MD, FHRS , Carlos D. Matos MD , Amit J. Thosani MD, FHRS , Christopher Thorne PhD , Benjamin D’Souza MD, FHRS , Isabella Alviz MD , Mohamed Gabr MD , Anil Rajendra MD, FHRS , Saumil Oza MD , Dinesh Sharma MD, MPH, FHRS , Carolina Hoyos MD , Matthew J. Singleton MD, FHRS , Chinmaya Mareddy MD , Alejandro Velasco MD , Paul C. Zei MD, PhD, FHRS , William H. Sauer MD, FHRS , Jorge E. Romero MD, FHRS\",\"doi\":\"10.1016/j.hrthm.2024.07.094\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>High-frequency, low-tidal volume (HFLTV) ventilation increases the efficacy and efficiency of radiofrequency catheter ablation (RFCA) of paroxysmal atrial fibrillation. Whether those benefits can be extrapolated to RFCA of persistent atrial fibrillation (PeAF) is undetermined.</div></div><div><h3>Objective</h3><div>The purpose of this study was to evaluate whether using HFLTV ventilation during RFCA in patients with PeAF is associated with improved procedural and long-term clinical outcomes compared to standard ventilation (SV).</div></div><div><h3>Methods</h3><div>In this prospective multicenter registry (REAL-AF), patients who had undergone pulmonary vein isolation (PVI) + posterior wall isolation (PWI) for PeAF using either HFLTV ventilation or SV were included. The primary efficacy outcome was freedom from all-atrial arrhythmias at 12 months. Secondary outcomes included procedural and long-term clinical outcomes and complications.</div></div><div><h3>Results</h3><div>A total of 210 patients were included (HFLTV=95 vs. SV=115) in the analysis. There were no differences in baseline characteristics between the groups. Procedural time (80 [66–103.5] minutes vs 110 [85–141] minutes; <em>P</em> <.001), total radiofrequency (RF) time (18.73 [13.93–26.53] minutes vs 26.15 [20.30–35.25] minutes; <em>P</em> <.001), and pulmonary vein RF time (11.35 [8.78–16.69] minutes vs 18 [13.74–24.14] minutes; <em>P</em> <.001) were significantly shorter using HFLTV ventilation compared with SV. Freedom from all-atrial arrhythmias was significantly higher with HFLTV ventilation compared with SV (82.1% vs 68.7%; hazard ratio 0.41; 95% confidence interval [0.21–0.82]; <em>P</em> = .012), indicating a 43% relative risk reduction and a 13.4% absolute risk reduction in all-atrial arrhythmia recurrence. There was no difference in long-term procedure-related complications between the groups (HFLTV 1.1% vs SV 0%, <em>P</em> = .270).</div></div><div><h3>Conclusion</h3><div>In patients undergoing RFCA with PVI + PWI for PeAF, the use of HFLTV ventilation was associated with higher freedom from all-atrial arrhythmias at 12-month follow-up, with significantly shorter procedural and RF times compared to SV, while reporting a similar safety profile.</div></div>\",\"PeriodicalId\":12886,\"journal\":{\"name\":\"Heart rhythm\",\"volume\":\"22 2\",\"pages\":\"Pages 432-442\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Heart rhythm\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1547527124030704\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart rhythm","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1547527124030704","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
High-frequency low-tidal volume ventilation improves procedural and long-term clinical outcomes in persistent atrial fibrillation ablation: Prospective multicenter registry
Background
High-frequency, low-tidal volume (HFLTV) ventilation increases the efficacy and efficiency of radiofrequency catheter ablation (RFCA) of paroxysmal atrial fibrillation. Whether those benefits can be extrapolated to RFCA of persistent atrial fibrillation (PeAF) is undetermined.
Objective
The purpose of this study was to evaluate whether using HFLTV ventilation during RFCA in patients with PeAF is associated with improved procedural and long-term clinical outcomes compared to standard ventilation (SV).
Methods
In this prospective multicenter registry (REAL-AF), patients who had undergone pulmonary vein isolation (PVI) + posterior wall isolation (PWI) for PeAF using either HFLTV ventilation or SV were included. The primary efficacy outcome was freedom from all-atrial arrhythmias at 12 months. Secondary outcomes included procedural and long-term clinical outcomes and complications.
Results
A total of 210 patients were included (HFLTV=95 vs. SV=115) in the analysis. There were no differences in baseline characteristics between the groups. Procedural time (80 [66–103.5] minutes vs 110 [85–141] minutes; P <.001), total radiofrequency (RF) time (18.73 [13.93–26.53] minutes vs 26.15 [20.30–35.25] minutes; P <.001), and pulmonary vein RF time (11.35 [8.78–16.69] minutes vs 18 [13.74–24.14] minutes; P <.001) were significantly shorter using HFLTV ventilation compared with SV. Freedom from all-atrial arrhythmias was significantly higher with HFLTV ventilation compared with SV (82.1% vs 68.7%; hazard ratio 0.41; 95% confidence interval [0.21–0.82]; P = .012), indicating a 43% relative risk reduction and a 13.4% absolute risk reduction in all-atrial arrhythmia recurrence. There was no difference in long-term procedure-related complications between the groups (HFLTV 1.1% vs SV 0%, P = .270).
Conclusion
In patients undergoing RFCA with PVI + PWI for PeAF, the use of HFLTV ventilation was associated with higher freedom from all-atrial arrhythmias at 12-month follow-up, with significantly shorter procedural and RF times compared to SV, while reporting a similar safety profile.
期刊介绍:
HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability.
HeartRhythm integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community.
The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal health care policies and standards.